Business Wire

MA-PRECISELY

17.5.2023 15:31:33 CEST | Business Wire | Press release

Share
Precisely Announces EngageOne RapidCX, Revolutionizing Customer Communications Management for Highly Regulated Industries

Precisely, the global leader in data integrity, today announced the launch of EngageOne RapidCX, bringing the latest innovation in customer communications management (CCM) to the market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230517005070/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Precisely, the global leader in data integrity, announces the launch of EngageOne RapidCX, bringing the latest innovation in customer communications management (CCM) to the market. (Photo: Business Wire)

RapidCX empowers organizations to provide a better, more effective customer experience through data-driven, personalized, communications. This is particularly important for highly regulated industries such as financial services, insurance, and telecommunications, where the pressure is on to deliver more personalized and dynamic customer experiences to stay competitive, while also navigating increasingly complicated regulatory requirements.

Announced at the Trust ‘23 Data Integrity Summit, RapidCX allows organizations to solve challenges such as disjointed customer communications, compliance with changing regulations, and siloed legacy systems to:

  • Improve Efficiencies – replace manual customer experience processes with an automated solution that enables business users to harness data from across all systems.
  • Enhance Customer Engagement – capture data-driven insights to quickly and easily personalize and automate omnichannel communications, including e-mails, SMS messages, chatbot conversations, interactive video and more.
  • Enable Better Governance – ensure compliance with end-to-end communications tracking, delivery tracing, and archiving. Easy-to-manage governance controls make even complicated industry regulations easier to follow.

“The launch of RapidCX is a significant industry event and a real game changer for Precisely, particularly in highly regulated markets,“ said Kaspar Roos, Founder & CEO at Aspire. “Precisely has brought together a wide variety of standalone capabilities into a comprehensive, fully managed cloud-based platform, providing a simplified way for customers to get access to modern customer-focused technologies without the need for extensive integration. The launch positions Precisely favorably to meet the needs of a new generation of CCM buyers found in marketing, customer experience, and the line-of-business.”

The announcement of the new platform is well-timed, with customer loyalty being harder to come by in recent years due to shifts in consumer behavior, rising competition, and economic pressures. In fact, a recent PwC survey showed that more than half of consumers (55%) would stop buying from a company, even if they otherwise liked them, after having several bad experiences – with a further 8% saying they would stop after just one negative experience.

With the rollout of RapidCX, organizations worldwide can now easily and dynamically deliver satisfying, personalized experiences, no matter how, where or when the customer chooses to interact. When combined with the Precisely portfolio of data integrity solutions, organizations can ensure they are powering customer communications delivery with trusted data, helping to win lasting loyalty and, ultimately, accelerate business growth.

“Businesses can no longer apply a one-size-fits-all approach to customer engagement. Today's customers expect extraordinary experiences, and trusted data is the cornerstone for delivering them,” said Greg Van den Heuvel, Executive Vice President and General Manager – Engage Solutions at Precisely. “Forward-thinking organizations are turning to cloud hosted integrated customer engagement platforms, fueled with accurate, consistent, and contextual data, to revolutionize their approach to customer communications.”

Learn more about RapidCX here.

About Precisely

Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005070/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release

First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno

BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release

Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures

IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release

IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye